Want to see IL:KMDA full AI Analyst Report?
KMDA Stock Chart & Stats
2533.00
-41.00(-1.90%)
At close: 4:00 PM EDT
2533.00
-41.00(-1.90%)
Day’s Range― - ―
52-Week Range1,899.20 - 2,806.07
Previous CloseN/A
Volume64.77K
Average Volume (3M)61.53K
Market Cap
₪1.46B
Enterprise Value1.09K
Total Cash (Recent Filing)₪69.66M
Total Debt (Recent Filing)₪11.72M
Price to Earnings (P/E)22.5
Beta0.64
Next Earnings
Nov 16, 2026EPS Estimate
39.15Next Dividend Ex-DateN/A
Dividend Yield5.04%
Share Statistics
EPS (TTM)0.38
Shares Outstanding57,694,270
10 Day Avg. Volume102,707
30 Day Avg. Volume61,533
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪4,202.10Price Target Upside65.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.46
Revenue Forecast (FY)₪202.22M
Bulls Say, Bears Say
Bulls Say
Improving Profitability And Operating Cash FlowKamada is converting stronger demand into profitable growth, with EBITDA, net income and operating cash flow all improving year over year. This supports reinvestment, product expansion and resilience across the plasma-derived therapeutics portfolio.
Conservative Balance SheetVery low leverage limits refinancing risk and gives Kamada flexibility to fund capacity, development programs or partnerships without depending heavily on debt. Improving equity returns also indicate better use of the company’s capital base.
Secured Plasma Supply And Commercial ExpansionThe multiyear agreement validates Kamada’s plasma collection investments and provides contracted demand and revenue visibility. Distribution expansion, biosimilar launches and broader product utilization could extend the platform’s growth beyond existing products.
Bears Say
Cooling Underlying Revenue GrowthAlthough recent quarterly performance improved, the broader growth trajectory has moderated materially from earlier expansion. Sustaining the 2026 outlook will depend on new plasma sales, biosimilar launches and continued adoption of marketed therapies.
Uneven Cash-flow ConversionPositive recent cash generation is encouraging, but historical volatility and free cash flow below accounting earnings indicate inconsistent conversion. Working-capital needs, production economics or timing effects could constrain internally funded growth.
Committed Plasma Capacity And Margin PressureContracted capacity improves revenue visibility but may limit room for additional external orders in the near term. At the same time, mix-driven gross-profit pressure could restrict margin expansion even as utilization and sales increase.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was 1899.20 and its highest was 2806.07 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is ₪1.46B.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Nov 16, 2026 which is in 81 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Aug 12, 2026. The company reported 51.02 earnings per share for the quarter, beating the consensus estimate of 33.222 by 17.798.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of 50.436 which represents an annual dividend yield of 5.04%. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 39.15.
How many shares outstanding does Kamada have?
Kamada has 57,694,270 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of 51.02 in its last earnings report, beating expectations of 33.222. Following the earnings report the stock price went down -3.146%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in IL:KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
₪4,202.10 (65.89% Upside)
₪4,202.10 (65.89% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.70%
12-Months-Change
Fundamentals
Return on Equity
5.04%
Trailing 12-Months
Asset Growth
2.11%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party pharmaceuticals. Under its proprietary segment, Kamada develops and sells treatments such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing cytomegalovirus in transplant recipients (including kidney, lung, liver, pancreas, heart, and heart/lung), WINRHO SDF for immune thrombocytopenic purpura (ITP) and to prevent Rh sensitization, HEPAGAM B for post-exposure prophylaxis and to stop hepatitis B recurrence after liver transplants, VARIZIG for post-exposure varicella prophylaxis, and GLASSIA, an intravenous therapy for Alpha-1 Antitrypsin Deficiency (AATD). Additional proprietary offerings include KamRho (D) IM for preventing hemolytic disease in newborns, KamRho (D) IV for immune thrombocytopenic purpura, and an antiserum specifically designed to treat snake bites from Vipera palaestinae and Echis coloratus. Through its distribution arm, Kamada provides a diverse portfolio of pharmaceuticals and medical devices. This includes BRAMITOB for chronic pulmonary infections, FOSTER for asthma management, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, the AEROBIKA OPEP device, RUPAFIN for allergic rhinitis and urticaria, IVIG for various immunodeficiency conditions, VARITECT for chickenpox and herpes zoster, ZUTECTRA and HEPATECT CP for hepatitis B, MEGALOTECT CP for cytomegalovirus, RUCONEST for angioedema attacks, heparin sodium injection for treating and preventing thromboembolic disorders, ALBUMIN for blood plasma, Factor VIII for hemophilia A, and Factor IX for hemophilia B. The distributed range also features IXIARO for Japanese encephalitis, VIVOTIF for Salmonella Typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, and ELIGARD for prostate cancer. Kamada employs a multi-channel commercial strategy, utilizing strategic partners to market its products within the United States and relying on a network of distributors for its international sales. Key strategic alliances include collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, the company's headquarters are located in Rehovot, Israel.
KMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: management reported record revenues, strong adjusted EBITDA and margins, sizable operating cash flow improvement, and secured a meaningful $50M plasma supply agreement while expanding distribution and biosimilar initiatives. Notable risks and concerns include a quarter-to-quarter gross profit shift due to product mix, a planned CFO departure, modest decline in cash after a dividend, and management's decision not to raise guidance despite strong H1 results. Overall, the positive financial momentum and strategic commercial wins outweigh the limited operational and corporate governance headwinds.View all IL:KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
4,202.10
▲(65.89% Upside)